查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
肺炎治疗药的全球市场:市场规模 - 各治疗药物，各流通管道，各年龄层，感染各类型，各地区展望，竞争策略，各市场区隔预测(～2032年)
市场调查报告书
商品编码
1159579

肺炎治疗药的全球市场:市场规模 - 各治疗药物，各流通管道，各年龄层，感染各类型，各地区展望，竞争策略，各市场区隔预测(～2032年)

Pneumonia Therapeutics Market Size- By Therapeutics, By Distribution Channel, By Age Group, By Infection Type - Regional Outlook, Competitive Strategies and Segment Forecasts to 2032
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 256 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球肺炎治疗药的市场规模，预计至2032年达到426亿2,000万美元，以8.3％的年复合成长率成长。

由于肺炎的盛行率增加，肺炎治疗药，成为扩大全球市场的重要要素。还有在预测期间内，预计社区型肺炎的频率增加，市场扩大挂上(放上)刺激。同时，对医药品和疫苗严格的规则被制定，变成市场扩大的阻碍因素。

本报告提供全球肺炎治疗药市场相关调查，市场动态，市场变数及预测，各治疗药、流通管道、年龄层、感染类型、地区的市场分析，企业简介等相关资讯。

目录

第1章 简介

  • 调查范围
  • 市场区隔分析

第2章 调查手法

  • 调查资料来源
  • 市场规模的估计
  • 资料的三角测量

第3章 摘要整理

第4章 市场动态

  • 促进因素，阻碍因素，机会，课题的分析
    • 促进因素
    • 阻碍因素
    • 机会
    • 课题
  • 全球肺炎治疗药市场上COVID-19的影响

第5章 市场变数及预测

  • SWOT分析
    • 优势
    • 弱点
    • 机会
    • 威胁
  • PESTEL分析
    • 政治形势
    • 经济形势
    • 社会形势
    • 技术形势
    • 环境形势
    • 法律上的形势
  • 波特的五力分析
    • 供给企业谈判力
    • 买方议价能力
    • 替代品的威胁
    • 新加入厂商的威胁
    • 竞争企业间的敌对关係
  • 热图分析

第6章 全球肺炎治疗药市场:各治疗药物，2019年～2032年(100万美元)

  • 预防疫苗
  • 治疗药
    • 抗菌药
    • 抗病毒药物
    • 抗真菌药物

第7章 全球肺炎治疗药市场:各流通管道，2019年～2032年(100万美元)

  • 医院
  • 医药品经销商
  • 其他

第8章 全球肺炎治疗药市场:各年龄层，2019年～2032年(100万美元)

  • 儿童
  • 成人
  • 老年人

第9章 全球肺炎治疗药市场:各感染类型，2019年～2032年(100万美元)

  • 院内肺炎(HAP)
  • 社区型肺炎(CAP)
  • 人工呼吸器相关肺炎(VAP)

第10章 全球肺炎治疗药市场:各地区，2019年～2032年(100万美元)

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 其他的欧洲
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 其他的亚太地区
  • 南美
    • 巴西
    • 阿根廷
    • 其他的南美
  • 中东、非洲
    • 沙乌地阿拉伯王国
    • 阿拉伯联合大公国
    • 其他的中东、非洲

第11章 企业简介

  • Abbott Laboratories
    • 企业概要
    • 财务预测
    • 产品概要
    • 最近的开发
  • Bayer AG
  • Eli Lilly & Company
  • Glaxosmithkline Plc.
  • Lupin Pharmaceuticals, Inc.
  • Merck KGAA
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • Teva Pharmaceuticals Industries Limited
简介目录
Product Code: HLCA2217

Global Pneumonia Therapeutics Market Overview:

According to SPER Market Research, the Global Pneumonia Therapeutics Market is estimated to reach USD 42.62 billion by 2032 with a CAGR of 8.3%.

An infection that affects the lower respiratory system is pneumonia. Additionally, pneumonia exhibits symptoms including shortness of breath, fever, chest discomfort, nausea, and vomiting. Alveoli, the lungs' air sacs, are filled with fluid or pus in pneumonia, which results in inflammation. It is frequently found in children and the elderly and is mostly brought on by microorganisms including fungi, bacteria, viruses, and parasites. It mainly affects persons with low immune systems.

The increased prevalence of pneumonia is a significant factor driving the expansion of the global market for therapies treating the condition. Additionally, throughout the anticipated period, an increase in the frequency of community-acquired pneumonia is anticipated to fuel market expansion. Additionally, it is anticipated that an increase in product releases following FDA clearance would assist the sector to generate the most income. Additionally, it is anticipated that a rise in clinical trials for the R&D of vaccines and medicinal compounds would support industrial expansion in the next years. The establishment of strict rules for pharmaceuticals and vaccines, however, impedes market expansion.

Impact of COVID-19 on the Global Pneumonia Therapeutics Market

On January 30, 2021, the World Health Organization designated the COVID-19 outbreak a public health emergency of global significance. A person with COVID-19 is especially vulnerable to pneumonia, which can result in wheezing and an accumulation of mucus in the alveoli. This is anticipated to fuel the market for pneumonia treatments. Additionally, it is anticipated that growth in R&D for the treatment of pneumonia associated with COVID-19 would help the market to produce significant revenue throughout the projection period. However, the COVID-19 shortage of workers as well as resource restrictions are anticipated to have a detrimental effect on the industry's growth throughout the projection period. In addition, the industry expansion has been slowed by the installation of strict government restrictions governing lockdown. Additionally, it is urgent to develop fresh products that can aid in the fight against COVID-19. Because of this, the market for pneumonia treatments is expected to produce more money throughout the forecast period.

Scope of the Report:

Market size available for years 2019-2032

Base year considered 2021

Forecast period 2022-2032

Segments covered By Access, By Component, By Type, By End User

Geographies covered: North America, Europe, Asia Pacific, Latin America, Middle East and Africa

Companies Covered Atos SE, Alioth LLC, Cardcom Technology, CardLogix Corporation, CPI Card Group, Eastcompeace, Fingerprint Cards AB, Gemalto NV, Giesecke & Devrient, HID Global Corporation, IDEMIA, Infineon Technologies AG., Texas Instruments, Watchdata Technologies.

Global Pneumonia Therapeutics Market Segmentation:

By Therapeutics: Based on the Therapeutics, Global Pneumonia Therapeutics Market is segmented as; Prevention Vaccines, Treatment Drugs {Antibacterial Drugs (Macrolide, Quinolones, Aminopenicillins, Macrolides, B-lactamase inhibitors, Cephalosporins, Tetracyclines, Glycopeptide antibiotics, Carbapenems, Others), Antiviral Drugs, Antifungal Drugs}.

By Distribution Channel: Based on the Distribution Channel, Global Pneumonia Therapeutics Market is segmented as; Hospitals, Pharmaceutical Stores, Others.

By Age Group: Based on the Age Group, Global Pneumonia Therapeutics Market is segmented as; Pediatric, Adult and Geriatric.

By Infection Type: Based on the Infection Type, Global Pneumonia Therapeutics Market is segmented as; Hospital-acquired pneumonia, Community-acquired pneumonia, Ventilator-associated pneumonia.

By Region: Due to rising geriatric populations, an ageing population, and an increase in both adult and paediatric multidrug resistance, North America had the largest revenue share and is predicted to keep it throughout the forecast period. These factors reinforce the need for development and rising R&D activities.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1 Research data source
    • 2.1.1 Secondary data
    • 2.1.2 Primary data
    • 2.1.3 SPER's internal database
    • 2.1.4 Premium insight from KOL's
  • 2.2 Market size estimation
    • 2.2.1 Top-down and Bottom-up approach
  • 2.3 Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1 Drivers
    • 4.1.2 Restraints
    • 4.1.3 Opportunities
    • 4.1.4 Challenges
  • 4.2. COVID-19 Impacts of the Global Pneumonia Therapeutics Market

5. Market variables and outlook

  • 5.1. SWOT analysis
    • 5.1.1 Strengths
    • 5.1.2 Weaknesses
    • 5.1.3 Opportunities
    • 5.1.4 Threats
  • 5.2. PESTEL analysis
    • 5.2.1 Political landscape
    • 5.2.2 Economic landscape
    • 5.2.3 Social landscape
    • 5.2.4 Technological landscape
    • 5.2.5 Environmental landscape
    • 5.2.6 Legal landscape
  • 5.3. PORTER'S five forces analysis
    • 5.3.1 Bargaining power of suppliers
    • 5.3.2 Bargaining power of Buyers
    • 5.3.3 Threat of Substitute
    • 5.3.4 Threat of new entrant
    • 5.3.5 Competitive rivalry
  • 5.4. Heat map analysis

6. Global Pneumonia Therapeutics Market, By Therapeutics, 2019-2032 (USD Million)

  • 6.1 Prevention Vaccines
  • 6.2 Treatment Drugs
    • 6.2.1 Antibacterial Drugs
      • 6.2.1.1 Macrolide
      • 6.2.1.2 Quinolones
      • 6.2.1.3 Aminopenicillins
      • 6.2.1.4 Macrolides
      • 6.2.1.5 B-lactamase inhibitors
      • 6.2.1.6 Cephalosporins
      • 6.2.1.7 Tetracyclines
      • 6.2.1.8 Glycopeptide antibiotics
      • 6.2.1.9 Carbapenems
      • 6.2.1.10 Others
    • 6.2.2 Antiviral Drugs
    • 6.2.3 Antifungal Drugs

7. Global Pneumonia Therapeutics Market, By Distribution Channel, 2019-2032 (USD Million)

  • 7.1 Hospitals
  • 7.2 Pharmaceutical Stores
  • 7.3 Others

8. Global Pneumonia Therapeutics Market, By Age Group, 2019-2032 (USD Million)

  • 8.1 Pediatric
  • 8.2 Adult
  • 8.3 Geriatric

9. Global Pneumonia Therapeutics Market, By Infection Type, 2019-2032 (USD Million)

  • 9.1 Hospital-acquired pneumonia (HAP)
  • 9.2 Community-acquired pneumonia (CAP)
  • 9.3 Ventilator-associated pneumonia (VAP)

10. Global Pneumonia Therapeutics Market, By Region, 2019-2032 (USD Million)

  • 10.1 North America
    • 10.1.1 United States
    • 10.1.2 Canada
    • 10.1.3 Mexico
  • 10.2 Europe
    • 10.2.1 Germany
    • 10.2.2 United Kingdom
    • 10.2.3 France
    • 10.2.4 Italy
    • 10.2.5 Spain
    • 10.2.6 Rest of Europe
  • 10.3 Asia-Pacific
    • 10.3.1 China
    • 10.3.2 Japan
    • 10.3.3 India
    • 10.3.4 Australia
    • 10.3.5 South Korea
    • 10.3.6 Rest of Asia-Pacific
  • 10.4 South America
    • 10.4.1 Brazil
    • 10.4.2 Argentina
    • 10.4.3 Rest of South America
  • 10.5 Middle East & Africa
    • 10.5.1 Kingdom of Saudi Arabia
    • 10.5.2 United Arab Emirates
    • 10.5.3 Rest of Middle East & Africa

11. Company Profiles

  • 11.1 Abbott Laboratories
    • 11.1.1 Company details
    • 11.1.2 Financial outlook
    • 11.1.3 Product summary
    • 11.1.4 Recent developments
  • 11.2 Bayer AG
    • 11.2.1 Company details
    • 11.2.2 Financial outlook
    • 11.2.3 Product summary
    • 11.2.4 Recent developments
  • 11.3 Eli Lilly & Company
    • 11.3.1 Company details
    • 11.3.2 Financial outlook
    • 11.3.3 Product summary
    • 11.3.4 Recent developments
  • 11.4 Glaxosmithkline Plc.
    • 11.4.1 Company details
    • 11.4.2 Financial outlook
    • 11.4.3 Product summary
    • 11.4.4 Recent developments
  • 11.5 Lupin Pharmaceuticals, Inc.
    • 11.5.1 Company details
    • 11.5.2 Financial outlook
    • 11.5.3 Product summary
    • 11.5.4 Recent developments
  • 11.6 Merck KGAA
    • 11.6.1 Company details
    • 11.6.2 Financial outlook
    • 11.6.3 Product summary
    • 11.6.4 Recent developments
  • 11.7 Novartis AG
    • 11.7.1 Company details
    • 11.7.2 Financial outlook
    • 11.7.3 Product summary
    • 11.7.4 Recent developments
  • 11.8 Pfizer, Inc.
    • 11.8.1 Company details
    • 11.8.2 Financial outlook
    • 11.8.3 Product summary
    • 11.8.4 Recent developments
  • 11.9 Sanofi S.A.
    • 11.9.1 Company details
    • 11.9.2 Financial outlook
    • 11.9.3 Product summary
    • 11.9.4 Recent developments
  • 11.10 Teva Pharmaceuticals Industries Limited
    • 11.10.1 Company details
    • 11.10.2 Financial outlook
    • 11.10.3 Product summary
    • 11.10.4 Recent developments